Literature DB >> 18650833

Detailed genetic characterization of the interleukin-23 receptor in psoriasis.

V E Garcia1, M Chang, R Brandon, Y Li, N Matsunami, K P Callis-Duffin, D Civello, C M Rowland, N Bui, J J Catanese, G G Krueger, M F Leppert, A B Begovich, S J Schrodi.   

Abstract

Using a multi-tiered, case-control association design, scanning 25 215 gene-centric SNPs, we previously identified two psoriasis susceptibility genes: IL12B and IL23R. These results have recently been confirmed. To better characterize the IL23R psoriasis-association, we used a fine mapping strategy to identify 59 additional IL23R-linked SNPs, which were genotyped in our three independent, white North American sample sets (>2800 individuals in toto). A sliding window of haplotype association demonstrates colocalization of psoriasis susceptibility effects within the boundaries of IL23R across all sample sets, thereby decreasing the likelihood that neighboring genes, particularly IL12RB2, are driving the association at this region. Additional haplotype work identified two 5-SNP haplotypes with strong protective effects, consistent across our three sample sets (OR(common)=0.67; P(comb)=4.32E-07). Importantly, heterogeneity of effect was extremely low between sample sets for these haplotypes (P(Het)=0.961). Together, these protective haplotypes attain a frequency of 16% in controls, declining to 11% in cases. The characterization of association patterns within IL23R to specific predisposing/protective variants will play an important role in the elucidation of psoriasis etiology and other related phenotypes. Further, this work is essential to lay the foundation for the role of IL23R genetics in response to pharmaceutical therapy and dosage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18650833     DOI: 10.1038/gene.2008.55

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  8 in total

1.  Association of IL23R polymorphisms with psoriasis and psoriatic arthritis: a meta-analysis.

Authors:  Kun-Ju Zhu; Cheng-Yao Zhu; Ge Shi; Yi-Ming Fan
Journal:  Inflamm Res       Date:  2012-06-17       Impact factor: 4.575

Review 2.  Paradoxical inflammation induced by anti-TNF agents in patients with IBD.

Authors:  Isabelle Cleynen; Séverine Vermeire
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2012-07-03       Impact factor: 46.802

Review 3.  The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature.

Authors:  Marina Talamonti; Simone D'Adamio; Luca Bianchi; Marco Galluzzo
Journal:  Mol Diagn Ther       Date:  2017-10       Impact factor: 4.074

Review 4.  Biology of interleukin-22.

Authors:  Kerstin Wolk; Ellen Witte; Katrin Witte; Katarzyna Warszawska; Robert Sabat
Journal:  Semin Immunopathol       Date:  2010-02-02       Impact factor: 9.623

5.  The Decay of Disease Association with Declining Linkage Disequilibrium: A Fine Mapping Theorem.

Authors:  Mehdi Maadooliat; Naveen K Bansal; Jiblal Upadhya; Manzur R Farazi; Xiang Li; Max M He; Scott J Hebbring; Zhan Ye; Steven J Schrodi
Journal:  Front Genet       Date:  2016-12-12       Impact factor: 4.599

Review 6.  Update on the etiopathogenesis of psoriasis (Review).

Authors:  Daciana Elena Branisteanu; Catalina Cojocaru; Roxana Diaconu; Elena Andrese Porumb; Anisia Iuliana Alexa; Alin Codrut Nicolescu; Ilarie Brihan; Camelia Margareta Bogdanici; George Branisteanu; Andreea Dimitriu; Mihail Zemba; Nicoleta Anton; Mihaela Paula Toader; Adrian Grechin; Daniel Constantin Branisteanu
Journal:  Exp Ther Med       Date:  2022-01-05       Impact factor: 2.447

Review 7.  Genetics of psoriasis and pharmacogenetics of biological drugs.

Authors:  Rocío Prieto-Pérez; Teresa Cabaleiro; Esteban Daudén; Dolores Ochoa; Manuel Roman; Francisco Abad-Santos
Journal:  Autoimmune Dis       Date:  2013-08-28

8.  Reflections on the Field of Human Genetics: A Call for Increased Disease Genetics Theory.

Authors:  Steven J Schrodi
Journal:  Front Genet       Date:  2016-06-08       Impact factor: 4.599

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.